Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo
- PMID: 24899100
- DOI: 10.3892/or.2014.3233
Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo
Abstract
It has been shown that overexpression of signal transducer and activator of transcription 3 (Stat3) contribute to the progression and metastasis of various solid tumors and that silencing Stat3 inhibits tumor growth in several types of cancer. Gene associated with retinoid-IFN-induced mortality 19 (GRIM-19), a Stat3-inhibitory protein, was identified as a potential tumor suppressor associated with growth inhibition and cell apoptosis by targeting the transcription factor Stat3 for inhibition. However, little is known about Stat3 and GRIM-19 roles in the tumor growth of thyroid carcinoma cells. In the present study, we developed a dual expression plasmid that co-expressed Stat3-specific siRNA and GRIM-19 (pSi-Stat3-GRIM-19) and transfected it into SW579 cells (thyroid carcinoma cell line) to evaluate its effects on cell proliferation, cell apoptosis, cell migration and cell invasion in vitro and tumor growth in vivo. Simultaneous expression of pSi-Stat3-GRIM-19 in SW579 cancer cells was found to significantly suppress the proliferation, migration and invasion in vitro and tumor growth in vivo, when compared to the controls either Stat3-specific siRNA or GRIM-19 alone. In conclusion, our data demonstrated that a combined strategy of co-expressed Stat3-specific siRNA and GRIM19 synergistically and more effectively suppressed thyroid tumor growth, and have therapeutic potential for the treatment of thyroid cancer.
Similar articles
-
Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth.Clin Cancer Res. 2008 Jan 15;14(2):559-68. doi: 10.1158/1078-0432.CCR-07-1176. Clin Cancer Res. 2008. PMID: 18223232
-
Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.Oncol Rep. 2014 Dec;32(6):2501-10. doi: 10.3892/or.2014.3503. Epub 2014 Sep 19. Oncol Rep. 2014. Retraction in: Oncol Rep. 2022 Feb;47(2):24. doi: 10.3892/or.2021.8235. PMID: 25242535 Retracted.
-
Upregulation of GRIM-19 suppresses the growth of oral squamous cell carcinoma in vitro and in vivo.Oncol Rep. 2014 Nov;32(5):2183-90. doi: 10.3892/or.2014.3423. Epub 2014 Aug 20. Oncol Rep. 2014. Retraction in: Oncol Rep. 2025 Oct;54(4):122. doi: 10.3892/or.2025.8955. PMID: 25174621 Retracted.
-
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.Cytokine Growth Factor Rev. 2017 Feb;33:1-18. doi: 10.1016/j.cytogfr.2016.09.001. Epub 2016 Sep 15. Cytokine Growth Factor Rev. 2017. PMID: 27659873 Free PMC article. Review.
-
GRIM-19 function in cancer development.Mitochondrion. 2011 Sep;11(5):693-9. doi: 10.1016/j.mito.2011.05.011. Epub 2011 Jun 2. Mitochondrion. 2011. PMID: 21664299 Review.
Cited by
-
Synergistic effects and mechanism of recombinant viral vector-mediated STAT1 overexpression and STAT3 silencing on glioma U251 apoptosis.Mol Biol Rep. 2025 May 22;52(1):482. doi: 10.1007/s11033-025-10585-1. Mol Biol Rep. 2025. PMID: 40402343 Free PMC article.
-
Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer.Oncol Lett. 2016 Feb;11(2):1242-1250. doi: 10.3892/ol.2015.4018. Epub 2015 Dec 9. Oncol Lett. 2016. Retraction in: Oncol Lett. 2022 Nov 14;25(1):9. doi: 10.3892/ol.2022.13595. PMID: 26893726 Free PMC article. Retracted.
-
Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014. PLoS One. 2014. PMID: 25375359 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous